Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.

Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

In a significant advancement for thoracic oncology within the Appalachian region, WVU Medicine has announced it is the first health care system in West Virginia to utilize pulsed electric field (PEF) ...

The American Lung Association is working to highlight the importance of lung cancer screening.

UCLA researchers have developed a lipid nanoparticle-based gene-editing approach capable of inserting an entire healthy gene into human airway cells, restoring key biological function in a laboratory ...

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.

Selpercatinib is a highly selective and potent RET kinase inhibitor evaluated as an adjuvant therapy in patients with early-stage RET fusion-positive NSCLC.

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion-positive NSCLC, signaling a ...

The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...